Investigating the role of phosphatases in lupus
Official title: Phosphatases in lupus
Funded at Beth Israel Deaconess Medical Center · NIH-11097076 · Data updated 2026-11-12
This study is looking at how a certain enzyme called PP2A affects the immune system in people with lupus, to see if changing its activity can help reduce inflammation and improve treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 7, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $558,045 |
| NIH project number | 1R01AI189475-01 |
| Project ID | NIH-11097076 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with systemic lupus erythematosus, particularly those experiencing significant immune dysfunction.
✕Less likely to help
Patients with other autoimmune diseases or those not diagnosed with lupus may not benefit from this research.
What this research studies
This research focuses on understanding how a specific enzyme, Protein Phosphatase 2A (PP2A), affects immune cell function in patients with systemic lupus erythematosus (SLE). The study aims to explore how PP2A influences the production of key immune signaling molecules and the metabolism of immune cells, particularly T regulatory cells. By conducting experiments in animal models, researchers will assess how manipulating PP2A can impact inflammation and autoimmunity, potentially leading to new therapeutic strategies for lupus patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for lupus by restoring normal immune function and reducing inflammation.
How similar studies have gone: Previous research has shown promising results in understanding immune regulation in lupus, suggesting that targeting metabolic pathways may be a viable approach.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Tsokos, George C — Beth Israel Deaconess Medical Center
- Study coordinator: Tsokos, George C
Related research
Other NIH-funded projects on the same topics.
-
Understanding how DIS3L2 helps keep RNA in check to help lupus patients
A physician-scientist team is studying how a watchdog molecule for RNA (DIS3L2) may drive lupus-related immune problems, with the goal of uncovering new paths to treatment.
-
Pathogenic T cells in discoid lupus erythematosus
A doctor-scientist at Yale is studying why certain immune T cells cause skin damage in discoid lupus, with the goal of finding ways to reduce scarring and improve health for patients, especially African American women.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
Immunostimulatory short non-coding RNAs and lupus
A study in people with lupus looks at tiny RNA pieces that may spark inflammation, to understand if they drive disease activity.
-
Antiviral factors that limit HIV in people with SLE
Researchers at Howard University are studying how immune factors in people with lupus may help limit HIV infection.
-
PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.